KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hims & Hers Health (HIMS) Other financing activities: 2019-2025

Historic Other financing activities for Hims & Hers Health (HIMS) over the last 2 years, with Sep 2025 value amounting to $349,000.

  • Hims & Hers Health's Other financing activities was N/A to $349,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2021, which is 282.93% up from last year.
  • Latest data reveals that Hims & Hers Health reported Other financing activities of $349,000 as of Q3 2025, which was down 80.68% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Hims & Hers Health's Other financing activities ranged from a high of $12.8 million in Q1 2021 and a low of $57,000 during Q2 2021.
  • Moreover, its 1-year median value for Other financing activities was $1.2 million (2025), whereas its average is $1.1 million.
  • Data for Hims & Hers Health's Other financing activities shows a peak YoY surged of 12,694.00% (in 2021) over the last 5 years.
  • Over the past 2 years, Hims & Hers Health's Other financing activities (Quarterly) stood at $57,000 in 2021, then followed by $349,000 in 2025.
  • Its last three reported values are $349,000 in Q3 2025, $1.8 million for Q2 2025, and $1.2 million during Q1 2025.